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Short Introduction
The initiation of insulin action first involves its binding
to a specific receptor on the cell membrane and this is followed
by the stimulation of glucose transport and intracellular glucose
metabolism.

Although the acute effects of insulin on glucose

transport have been well characterized,

the effects of more chronic

exposure to insulin are less well defined.

These effects are of

general interest in understanding insulin physiology,

and assume

clinical importance in understanding what role hyperinsulinemia
plays in the insulin resistance associated with obesity
maturity-onset diabetes

(5-11), uremia

(12-14),

(1-4),

acidosis

(15),

and

other insulin resistant states.
Recently,

strong evidence has been provided to support the

concept that prolonged insulin exposure,
and in vivo

(16-20),

both in vitro

(15-18)

is capable of leading to a decrease in the

number of insulin receptor sites on the cell surface.

However,

the

metabolic consequence of this decrease in receptor binding has yet
to be established.
Much less is known about the effect of prolonged in vitro or
in vivo hyperinsulinemia on glucose transport and metabolism.
et.

al. have documented an increase in 2-deoxyglucose

(2-DOG )

Olefsk}

transport

by adipocytes obtained from rats chronically made hyperinsulinemic
with a 14 day protocol of insulin injections
the insulin clamp technique in man,

(21,

22).

Employing

Soman and DeFronzo have demon¬

strated a small but significant increase in overall glucose metab¬
olism following 3-5 hours of hyperinsulinemia

(20).

However,

other

studies have failed to document an increase in cellular glucose
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transport following a prolonged in vivo
exposure to insulin.

Instead,

(19) or in vitro

these studies

(18,

19)

(18)

found a

decrease in tissue sensitivity to insulin and have attributed
this to the decrease in receptor number which followed prolonged
insulin exposure

(18,

19).

The present study was undertaken:

1)

to examine the rate

of overall in vivo glucose metabolism during sustained,
hyperinsulinemia and 2)

to evaluate glucose transport by rat soleus

muscle following prolonged in vivo hyperinsulinemia.
this goal,

physiologic

the euglycemic insulin clamp technique

To accomplish

(23) was approp¬

riately modified to allow study of the unanaesthetized rat.

With

this technique a steady-state plateau of hyperinsulinemia can be
achieved while maintaining the plasma glucose concentration con¬
stant at the basal level.
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Introduction

I.

Glucose Transport
Following the binding of insulin to a cell surface receptor,

glucose transport is activated and this represents the first step
in the cellular metabolism of glucose.

Stimulation of glucose

transport is extremely sensitive to insulin and occurs at hormone
concentrations well within the physiologic range.

Most importantly,

insulin-stimulated glucose metabolism in vivo appears to represent
a primary effect on glucose transport rather than a stimulation of
intracellular glucose metabolism

(24,

25).

Early studies of glucose transport were performed by examining
glucose disappearance from the media

(26)

or by the chemical deter¬

mination of non-metabolized glucose analogues taken up by the cell
(27,

28).

More recently, radioactively-labelled non-metabolized

glucose analogues,
glucose

(2-DOG),

transport.
metabolized
of

including 3-O-methylglucose

(3-0-MG)

and 2-deoxy-

have been employed to study cellular glucose

3-0-MG is transported into the cell but not further
(27).

However,

there is also a significant efflux

3-0-MG from the cell and uptake actually represents the sum of

influx and efflux.

The intracellular accumulation of 3-0-MG proceeds

until a steady-state equilibrium is reached.

Thus,

the uptake of

3-0-MG reflects glucose transport only if initial rates of uptake
are measured,

i.e.,

before significant intracellular accumulation

of 3-0-MG has occurred and the rate of efflux becomes quantitatively
important.

Consequently,

special methodology

(29)

is necessary

to analyze the initial rapid rates of 3-0-MG uptake and this feature

_ 4 -

makes the study of 3-OMG transport difficult.
2-deoxyglucose

(2-DOG)

is transported into the cell and phosphory-

lated by the enzyme hexokinase
phosphate

(2-DOG-P)

In contrast to 3-0-MG,

(28).

However,

2-deoxyglucose-

is not further metabolized

(28).

Under con¬

ditions where transport of 2-DOG is rate-limiting and phosphory¬
lation is rapid,

little free 2-DOG accumulates within the cell

and there is no significant efflux of 2-DOG from the cell.

Thus,

uptake of 2-DOG into the cell is linear with time and this feature
greatly facilitates

study of glucose transport with this analogue.

Early studies by Kipnis and Cori

(28)

demonstrated that 2-DOG

was transported by rat diaphragm and that glucose and 2-DOG had
similar affinities for the transport system.

Furthermore,

uptake

was found to be linear even under conditions of high rates of
2-DOG transport

(28).

All intracellular deoxyglucose was present

as the phosphorylated derivative indicating that the hexokinose
enzyme was not rate-limiting.

Thus,

2-DOG uptake appeared to pro¬

vide a good measure of glucose transport into the cell.
Most of the initial studies on glucose transport employed rat
diaphragm.

However,

diaphragm is a constantly contracting muscle

and subsequent studies have shown that it does not reflect typical
skeletal muscle

(30).

Therefore, more recent studies have employed

soleus muscle which is composed mainly of slow-twitch red fibers
and is more representative of whole body skeletal muscle mass.
The soleus muscle can be isolated as an intact preparation without
damage to the muscle fibers

(26).

Uptake of 2-DOG has been shown

to be linear at a 2-DOG concentration of 0.5
periods of time

(31).

mM for prolonged

Transport of 2-DOG in soleus muscle is

5

thought to be rate-limiting since:

1)

lOx less than for transport,

and 2)

intracellular concentrations

of free 2-DOG are very small

(31).

II.

the Km for hexokinase is

Insulin-Stimulated Glucose Transport
Insulin stimulation of glucose transport is thought to involve

three steps:
ceptors,

2)

1)

insulin binding to specific plasma membrane re¬

coupling between occupied receptors and glucose

transport units,

and 3)

activation of glucose transport units.

Insulin Binding
The importance of insulin receptor binding in the activation
of cellular glucose transport was first suggested by the observa¬
tion that when adipocytes were treated with trypsin insulin binding
was diminished and this was parallelled by a decrease in cellular
glucose transport

(32,

33).

More recently,

the relationship between

insulin receptor binding and glucose transport activation has been
examined in adipocytes

(34-37)

and soleus muscle

(31).

Radioligand binding has been used to define insulin receptors
on the plasma membrane

(38).

present if the binding of
urable and 2)
insulin.
gators

125

Such receptors are assumed to be
I-insulin can be shown to be 1)

sat¬

competitively inhibited by the addition of unlabelled

Using such radioligand binding systems several investi¬
have attempted to examine the relationship between insulin

binding and insulin-mediated activation of the glucose transport
system

(31,

34-37).

Insulin stimulation of glucose transport has

been shown throughout the range of physiological insulin concen-

6

trations

(31,

34-37).

However, half-maximal stimulation of glu¬

cose transport occurs at insulin concentrations where only 5%
receptor occupancy is present,

and maximal stimulation occurs

where approximately 20% of receptors are bound by insulin
34-37).

The term spare receptors

(31,

34-37)

(31,

has been used to

describe the remaining 80% of the receptors beyond those necessary
to elicit a maximal biologic response.
Interpretation of spare receptors is complicated by the early
observation that receptor binding affinity is not uniform but
decreases with receptor occupancy

(38,

compatible with the existence of 1)

39).

This observation is

two or more distinct popula¬

tions of receptors with different fixed binding affinities or 2)
a uniform population of receptors which display site to site inter¬
actions with modification of binding affinity as receptor occupancy
changes.

Distinct receptor populations might suggest that high

affinity receptors are physiologically active while low affinity
receptors are inactive.

However, Demeyts

et.

al.

(39)

demon¬

strated the conversion of high affinity to low affinity sites when
receptor occupancy was increased.

These experiments provided

evidence that a uniform population of binding sites exists and is
capable of negative cooperativity in the binding of insulin.

Thus,

insulin receptors may represent a uniform population of sites
that are physiologically equivalent.

It is postulated that

occupancy of an equal number of any random insulin receptors will
produce an equivalent response.

7

Glucose Transport Activation
The mechanism of insulin stimulation of glucose transport has
been examined by Olefsky

et.

in isolated rat adipocytes.
2-DOG concentration.

al.

(34-37)

employing 2-DOG uptake

Transport is a function of extracellular

By analogy to an enzymatic model,

insulin

activation can be viewed as representing an increase in Vmax for
the system rather than an alteration in the Km or affinity for
2-DOG

(34).

Based on similar activation energies,

insulin-stimulated transport,

for basal and

the insulin induced increase in Vmax

may represent a recruitment of new transport units rather than
enhanced mobility of already active units
Recently,

(34).

cytochalasin-B binding has been employed to study

glucose transport activation by insulin

(40,

41).

Cytochalasin-B

binding sites are thought to be closely related to the glucose
transport system

(40,

41)

since:

1)

low concentrations of cyto¬

chalasin-B inhibit glucose transport and

2)

the effectiveness of

sugars in inhibiting cytochalasin-B binding is

stereo-specific and

related to their affinity for the glucose transport system.

An

increase in plasma membrane cytochalasin-B binding and a stoichio¬
metric decrease in microsomal membrane cytochalasin-B binding are
correlated with insulin activation of glucose transport i.in rat
adipocytes

(41,

42).

Thus,

these results suggest that insulin

activation of glucose transport may involve the recruitment of new
transport units into the plasma membrane from an intracellular
microsomal pool.

i-
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III.

Effects of Prolonged Insulin Exposure
The acute stimulating effects of insulin on glucose transport,

glycolysis,

and glycogen synthesis have been well studied in vitro

in adipocytes

(34-37)

and skeletal muscle

(31).

Similarly,

the

acute stimulation of glucose utilization by peripheral tissues has
recently been examined in vivo during experimental hyperinsulinemia
in man

(23).

In contrast,

the effects of prolonged in vitro or

in vivo insulin exposure on glucose metabolism have not been well
defined.

These effects are important not only in understanding

the physiology of insulin, but also in understanding what role
chronic hyperinsulinemia plays in insulin resistant states.
Difficulty in studying the effects of prolonged insulin ex¬
posure has stemmed from problems 1)

in maintaining tissue viable

in vitro for extended periods of time

and

2)

in developing a

suitable model of hyperinsulinemia which maintains the plasma
glucose concentration constant.

Although improved tissue culture

techniques have made it possible to study the effects of chronic
in vitro insulin exposure,

the study of chronic in vivo hyperin¬

sulinemia has proven difficult.

Experimental models of chronic

hyperinsulinemia have been developed in the rat

(19,

21,

22)

but

have been associated with wide fluctuations in plasma glucose
levels.
(23)

Development of the euglycemic insulin clamp technique

has been important in the study of hyperinsulinemia in man,

although studies to date have examined hyperinsulinemia for only
3-5 hour periods

(20).

9

Hyperinsulinemia and decreased receptor binding
Interest in the effect of changes in circulating insulin
levels on its own receptor were first raised by the frequently
observed inverse correlation between fasting plasma insulin con¬
centrations and insulin receptor binding.

This inverse correl¬

ation has been demonstrated in normal man (5),
obesity
(1,

(1-4), maturity-onset diabetes

43-45)

and carbohydrate feeding

(5,

(1,

43,

6)

in subjects with
and following fasting

46).

Similar obser¬

vations have been made in animal models of obesity
streptozotocin-induced diabetes

(51-54),

(31,

47-50)

and following fasting

(53-

55) .
Both in vitro

(16-18)

and in vivo

(19,

20,

56)

experiments have

established that hyperinsulinemia leads to a decrease in insulin
receptor binding.

Down-regulation of insulin receptors was first

demonstrated in vitro by

Gavin et.

al.

(16) who found a decrease

in insulin receptor binding in cultured lymphoblastoid cells fol¬
lowing a 5-16 hour exposure to supraphysiologic concentrations
of insulin

(16).

erature dependent

This effect was time,
(16).

concentration,

(10 mM)

and temp¬

The decrease in insulin receptor binding

was due to a decrease in receptor number without any change in
receptor binding affinity

(16).

Decreased receptor binding has

also been demonstrated at more physiologic insulin concentrations
in cultured rat hepatocytes following a 16 hour exposure to 1 nM
of insulin

(17).

Down-regulation of insulin receptor binding in

vitro has also been shown in rat adipocytes following exposure to
pharmacologic doses of insulin
doses

(18).

(10.5 nM)5 but not to physiologic

10
Down-regulation in vivo has also been observed following ex¬
perimental hyperinsulinemia.

Rat adipocytes show a 40% decrease

in insulin receptor binding in animals maintained on a chronic 14
day regime of NPH insulin injections

(19).

The plasma insulin

level was reported to be 65 ± 5 '/HJ/ml 12 hours after the last dose
of NPH insulin

(19).

insulin levels,

Thus,

it is likely that much higher plasma

in excess of 150-200 _-/CrU/ml were reached during

this experiment.

The interpretation of these changes is also some¬

what obscured by the large fluctuations in plasma glucose levels
that occured during this study.

Less prolonged exposure to in

vivo hyperinsulinemia has also been shown to decrease insulin
receptor binding in man (20,

56).

Sustained hyperinsulinemia of

3-5 hours duration produced by the euglycemic insulin clamp technique
resulted in a 25-30% decrease in monocyte binding at insulin levels
of 31 ± 2 ^U/ml

(20).

A greater decrease

(40%)

in insulin re¬

ceptor binding was observed with plasma insulin levels of 102 ± 6
^/t<U/ml

(20).

technique

Hyperinsulinemia produced by the quadruple infusion

(insulin,

glucose,

epinephrine,

and propranalol)

also

resulted in decreased insulin receptor binding with steady-state
insulin levels of 108-118 y^U/ml
hyperinsulinemia
glycemia,

(27-31

When a lesser degree of

was created with concomitant hyper¬

a decrease in insulin receptor binding was also observed

after 5 hours

(56).

This was attributed to a decrease in receptor

binding affinity for insulin
Thus,

(56).

(56).

the phenomenon of down-regulation (38,

57,

58) has been

demonstrated for insulin receptors following both in vitro and in
vivo exposure to insulin, both in man and animals.

Most importantly,

-
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the phenomenon of down-regulation has been demonstrated with
insulin concentrations in vivo which are well within the physiologic
range and which have commonly been observed in the post-prandial
state and in insulin resistant states.

As previously discussed,

present receptor theory would predict that a decrease in insulinmediated glucose metabolism should accompany a decrease in insulin
receptor binding.
in "sensitivity"

More specifically,
(59)

to insulin,

one would expect a decrease

i.e.,

an increase in the concen¬

tration of insulin required to elicit half-maximal stimulation of
the

full insulin response.

In fact,

any concentration of insulin

below that which achieves a maximal effect would be expected to
have a decreased effect.

In contrast,

decrease in "responsiveness"

(59)

one would not expect a

to insulin,

i.e,,

a change in the

maximal biological response that can be achieved at any concentration
of hormone, because at increasing concentrations of insulin, binding
of spare receptors should achieve a sufficient receptor occupancy
to elicit the maximal biological response.
in the dose response

Thus,

a rightward shift

curve with normalization at maximally effective

insulin concentrations is the predicted consequence of a decrease in
insulin receptor binding.

Hyperinsulinemia and glucose metabolism
Definition of the effects of prolonged insulin exposure on
glucose metabolism requires the study of tissues active in glucose
metabolism following either in vitro or in vivo exposure to insulin.
Livingston et.

al.

studied rat adipocytes following a 17 hour in

vitro exposure to 3.5-10.5

nM of insulin

(18).

This in vitro

12
exposure to supra-physiologic doses of insulin produced a rightward
shift in the insulin dose response curve, but no change in either
basal or maximal insulin-stimulated rates of glucose transport.
Similar findings have been reported by Olefsky et.

al. who

studied 2-DOG transport in adipocytes isolated from rats made
chronically hyperinsulinemic in vivo with a 14 day regime of twice
daily NPH insulin injections

(19).

However,

subsequent studies

from the same lab have demonstrated a significant increase in both
basal and maximal insulin-stimulated 2-DOG transport in rats sim¬
ilarly treated

(21,

22).

Although these results are inconsistent,

the latter data suggest that chronic in vivo hyperinsulinemia may
increase cellular glucose transport.
maintain euglycemia in these animals
ation of these results.
22)

However,

the failure to

complicates the interpret¬

This model of hyperinsulinemia

(19,

21,

in fact represents the combined effects of both prolonged

insulin exposure and changes in plasma glucose concentration.
Despite free access to 5% glucose drinking water and sugar cubes,
the hyperinsulinemic animals were markedly hypoglycemic compared
to controls which were both hyperglycemic
mg/dl)

and hyperinsulinemic

(plasma glucose = 152 ± 5

(plasma insulin = 29 ± 3y*U/ml).

Plasma

glucose concentration was measured only at the time of sacrifice
which was 12 hours after the last insulin dose.
indicate that many,

if not all,

The results

of the hyperinsulinemic rats

were frankly hypoglycemic throughout a significant period of the
2 week study.

The authors attempted to negate the effects of

hypoglycemia by treating another group of rats with injections of
20% glucose given 4 times daily to prevent hypoglycemia
However,

(19,

21,

22),

these animals were subject to large fluctuations in plasma

-
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glucose during the day with periods of marked hyperglycemia.

Al¬

though these authors have concluded that chronic in vivo hyperinsulinemia results in an increase in cellular glucose transport
(21,

22),

significant changes in plasma glucose concentration were

clearly present and it is also likely that changes in counterregulatory hormones also occurred.

Both of these factors could

have potentially contributed to the findings in this model.
The development of the euglycemic insulin clamp technique
(23)

has made it possible to study the effects of prolonged hyper-

insulinemia on in vivo glucose metabolism, while maintaining plasma
glucose concentration constant at the basal level and avoiding the
release of counter-regulatory hormones

(20).

With this technique,

a prime-continuous insulin infusion is administered intravenously
to rapidly achieve steady-state hyperinsulinemia while euglycemia
is maintained by a variable glucose infusion based on a negative
feed back principle

(23).

Since hyperinsulinemia suppressed hepatic

glucose production and since
under these conditions

(23),

urinary glucose loss is negligible
the glucose infusion rate required to

maintain euglycemia represents a measure of the amount of total in
vivo insulin-stimulated glucose metabolism.
Soman and DeFronzo

Using this technique,

(20) have demonstrated a small but significant

increase in in vivo glucose metabolism during the 3-5 hour period
of hyperinsulinemia at two different plasma insulin levels
100

U/ml).

(30 and

The increase in insulin-stimulated glucose metab¬

olism occurred despite a 30-40% decrease in insulin receptor binding
to circulating monocytes

(20).

However,

since the monocyte

not a target tissue for insulin-mediated glucose metabolism,

is
studies
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examining changes in cellular glucose transport or metabolism
could not be performed.

Similar results have been reported using

the quadruple infusion technique in man

(56), but again changes in

cellular glucose transport and metabolism could not be evaluated,
since circulating erythrocytes were employed and this tissue is
also not a target tissue for insulin-mediated glucose metabolism.

V.

Clinical significance of hyperinsulinemia
Interest in the effects of chronic in vivo hyperinsulinemia

on glucose metabolism has been prompted by a clinical interest in
what role hyperinsulinemia might have in insulin resistant states.
An inverse relationship between fasting plasma insulin concentration
and insulin receptor binding,

and a positive correlation between

decreased insulin binding and decreased insulin action in vivo,
have been observed in insulin resistant states including obesity
(1-3)

and

maturity - onset diabetes

(5,

6)

in man.

The data discussed above provide strong evidence that hyper¬
insulinemia per se leads to a decrease in insulin receptor binding
(16-20,

56)

and suggest that hyperinsulinemia may also play an

important role in the decrease in insulin receptor binding observed
in insulin resistant states.

However,

the metabolic consequence of

decreased receptor binding has not been directly established.

De¬

creased receptor binding has been shown to correlate with decreased
insulin sensitivity in vivo in obese man
rodents,

(1,

2,

3).

In obese

a decrease in receptor binding has also been correlated

with a decrease in insulin sensitivity in vitro in adipocytes
and

skeletal muscle

(31).

However,

(50)

in addition obese animals also

demonstrate a decrease in tissue responsiveness to insulin both

-
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in adipocytes

(50,

60)

and in skeletal muscle

(31).

Although

hyperinsulinemia may be responsible for the receptor-mediated
decrease in insulin sensitivity, what role,

if any,

hyperinsulin-

emia plays in the decreased tissue responsiveness to insulin
remains to be defined.
The relationship between insulin resistance,

hyperinsulinemia,

and decreased receptor binding in maturity - onset diabetes is even
less clear.

Although a decrease in insulin receptor binding has

been correlated with a decrease in in vivo insulin sensitivity
those diabetics did not manifest fasting hyperinsulinemia.
more,

(5),

Further¬

other studies have failed to correlate decreased receptor

binding with decreased in vivo insulin sensitivity

(6).

Thus,

what role hyperinsulinemia plays,and the mechanism of insulin
resistance, in maturity-onset diabetes is unclear.
Streptozotocin-treated diabetic rats are hypoinsulinemic and
demonstrate an increase in both insulin receptor binding and in
vitro tissue sensitivity to insulin (51,
addition, adipocytes from these animals

52,

54).

However,

show a decrease in both

basal and maximal insulin-stimulated glucose transport
and glucose oxidation (51).

in

In contrast,

(51,

52)

soleus muscles from

similar animals showed only an increase in tissue sensitivity
to insulin (54).

At least in adipocytes,

these hypoinsulinemic

animals appear to have a defect in the glucose transport system
per se.

Similar results have been observed in hypoinsulinemic

animals following prolonged fasting (53-55).

It has not yet been

established whether these "post-receptor" defects are a direct
effect,

a secondary effect,

insulin levels.

or independent of decreased circulating

Although other explanations are possible,

these

-
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findings are compatible with a decrease in circulating insulin
levels per se leading to a decrease in cellular glucose metabolism.
In summary,
well studied,

although the acute effects of insulin have been

the effects of prolonged insulin exposure on glucose

metabolism are not well defined.

The effects of chronic hyperin-

sulinemia are of importance not only in the understanding of
insulin physiology, but also in the understanding of insulin re¬
sistance in hyperinsulinemic states.

17
Methods

Animals
Fifty-five male Sprague Dawley rats

(156 ± 3 grams body weight)

were maintained in a constant temperature room with a 12 hour light
cycle.

All studies were performed in the post-absorptive state

after a 12-14 hour overnight fast.

Animals were allowed free

access to drinking water until the start of the study.
Four days prior to study,

chronic indwelling catheters

(PE-50

polyethylene tubing) were inserted into the jugular vein and carotid
artery for infusions and withdrawal of blood samples respectively.
Animals were anesthetized withNembutol
weight,

IP)

(0,08cc/100 grams body

and a vertical midline incision was made to expose

the right internal jugular vein and carotid artery.

The venous

catheter was inserted into the jugular vein and passed via the
superior vena cava into the right atrium.

The carotid artery

catheter was passed to the origin of the right brachiocephalic
artery.

The catheters were secured in place with 4-0 silk and

the distal ends were tunnelled subcutaneously to the dorsum of
the neck where they exited via a skin incision.

The animals recov¬

ered quickly after the surgical procedure and were eating and
drinking within 12 hours.
of heparinized saline

Catheters were flushed daily with 0.2 cc

(0.9% saline + 100 U/ml heparin)

to maintain

patency.
All animals were studied 4-5 days following catheter placement.
At the time of study,

they were restrained in a plexiglass cage

which allowed them to rest comfortably but limited them from moving

'
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about.

The catheters exited through a hole in the top of the

cage.

Euglycemic Insulin Clamp
To produce sustained physiologic elevations of plasma insulin,
a priming infusion of insulin was administered during the first 8
minutes and this was followed by a continuous insulin infusion at
the rate of 1.75 y^U/gram body weight per minute

(Table 1).

The

continuous insulin infusion was maintained throughout the three
hour study period and raised steady-state levels by approximately
SOy^U/ml above fasting plasma insulin.

The insulin infusion was

prepared from regular crystalline porcine insulin
Indianapolis,

Ind.)

in 0.9% saline;

300 mg of

(Lilly Co.,

albumin were added

to each 100 ml of normal saline to prevent adherence of the insulin
to the glassware and plastic tubing.
During the 3 hour period of hyperinsulinemia,

the plasma

glucose concentration was maintained constant at the basal fasting
glucose level by the infusion of a 5% glucose solution.

The glucose

infusion is started 4 minutes following initiation of the insulin
infusion.

The initial glucose infusion was empirically set at

7 y^g/gram body weight per minute.

At 8 minutes the glucose

infusion rate was increased to 10 /^g/g*min.,
to 14 ^g/g •

min.

and at 11 minutes

Subsequent alterations in the glucose infusion

rate were based on determinations of arterial plasma glucose drawn
at 10-15 minute intervals.

The first glucose determination was

obtained 15 minutes after initiation of insulin infusion.
initial experiments,

In the

the glucose infusion rate was adjusted using

19

TABLE 1.

The Prime Continuous Insulin Infusion

Employed During Euglycemic Insulin Clamp

Time (Min.)

Insulin Infusion Rate (y^U/g Body Wt. Min.)

0-2

3.36

2-8

2.40

8-180

1.75

20

a negative feed back formula as previously described by DeFronzo
et.

al.

(23).

This formula takes into account changes in the rate

of glucose metabolism as well as changes in the size of the glucose
pool.

After the first few studies all changes in the glucose

infusion rate were made empirically based on experience gained
from the initial studies.
Plasma insulin concentration was determined in the basal
state and at 60,

120,

and 180 minutes during insulin infusion.

Plasma epinephrine was determined at 180 minutes.
Twenty-three rats served as a control group.

These animals

were treated similarly to the above group except that they received
a 3 hour infusion of normal saline instead of the glucose-insulin
infusions.

Blood samples for insulin and glucose determinations

were obtained as described above.

Computations

Glucose Metabolism ( M ).
euglycemia,

Under steady-state conditions of

the glucose infusion rate

(INF) must be equal to the

amount of glucose taken up and metabolized by all tissues and pro¬
vides a measure of insulin-stimulated glucose metabolism.
assumes that hepatic glucose production

(HGP)

To the extent that HGP is not suppressed,

This

is complete suppressed.

the rate of endogenous

glucose production must be added to the glucose infusion rate to de¬
termine the actual rate of tissue glucose metabolism.
study HGP was not directly determined.

In the present

These studies are presently
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being performed and until completed it should be noted that the
rates of glucose metabolism presented in Table 3 may be a slight
underestimate of the true rate of glucose metabolism.
During the insulin clamp study,
do occur.

small changes in plasma glucose

These changes represent additions of glucose to,

tractions from,

or sub¬

the glucose space caused by a change in the rate of

tissue glucose metabolism.

Thus,

corrected by a space correction
glucose metabolism

( M ).

the infusion rate

(SC)

(INF) must be

to arrive at the true rate of

Therefore,
M = INF - SC

The space correction is given by the formula:
SC =

(G2-G-^) x 10 x (0.19 x body weight)
(T2~Ti)

Where

(G^-G^)

x body weight

is the change in plasma glucose in mg/dl,

(G^-G].)

x ^

is the change in mg/1,

(0.19 x body weight) was used to approximate

the glucose space,

(T2 - T^)

and

is the time interval.

In this study

glucose metabolism ( M ) was calculated for 40 minute time inter¬
vals and in this case the space correction formula reduces to:
SC =

^-Gp

x 0.0475

Units for SC are expressed as /g/gram body weight per minute of
glucose added or subtracted.
The metabolic clearance rate
as described previously

(MCR)

for insulin is calculated

(23).

_ insulin infusion rate_
increase in plasma insulin above basal
MCR is expressed in ml/gram body weight per minute when the insulin
infusion rate is in^U/gram body weight per minute and the increase
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in steady-state insulin levels above basal is in _/^U/ml.

This

assumes that endogenous insulin secretion remains constant during
insulin infusion.

To the extent that elevation of plasma insulin

leads to a decrease in basal insulin secretion

(23),

the metabolic

clearance rates given in Table 3 may be slightly overestimated.
Statistical analyses were done by the unpaired student's
t-test

(61).

All data are presented as mean ± SE.

Deoxyglucose Transport
Following 180 minutes of insulin-glucose or saline infusion
animals were sacrificed.

Nembutol

(0.2 cc/100 grams body wt.)

was administered through the venous catheter and within 10-15
seconds both legs were removed.
ligated with 4-0 silk,

Soleus muscle was exposed,

and excised intact.

taught onto stainless steel rings
with 0.9% saline,

tendons

Muscles were tied

(3/4 inches diameter),

and placed in glass incubation vials.

rinsed
Incu¬

bations were conducted in a shaking water bath at 20 °C under a
95% 0^

5% CO2 atmosphere.

Muscles were initially preincubated for 15 minutes in a 2 mM
pyruvate Krebs bicarbonate albumin buffer:
NaCl,

3 mMKCl,

1,2 mM MgSO^ 2.5 mM CaCl2,

NaHCO^ and bovine serum albumin
minute preincubation

Krebs ringer

(120 mM

1,2 mM KH^PO^) with 24nM

(2 g/100 cc).

Following the 15

period, muscles were removed and the final

incubation was carried out for 3 hours in Krebs bicarbonate albumin
buffer

(pH 7.4).

One muscle from each animal was incubated in

the absence of insulin, while the other muscle was incubated with
insulin at one of the following concentrations:

0.5,

0.75,

1.0,

23
5•0 ,

10.0 mg/ml.
Following the 3 hour incubation period,

determined by the addition of 0.2 mM
incubation vial)

glucose transport was

^C-2-deoxy-D-glucose

(New England Nuclear,

Boston, MA)

(1/Ci/

for 15 minutes.

Muscles were removed and washed 6 times for 5 minutes in 5 cc of
an ice-cold 0.9% NaCl + 500 mg/lOOcc human serum albumin solution.
Sutures were then removed,

and the tendons were trimmed.

muscles were dried at 120°C for 24 hours, weighted,
in 1 ml of 1 N NaOH for 12 hours.
with distilled water,

The

and dissolved

Following dilution to 10 ml

a 1 ml aliquot was taken for counting.

Analytic Methods
Plasma glucose determinations were made on 50^/fL samples,ob¬
tained from the carotid artery,using the glucose oxidase method
(Yellow Springs Instruments, Model 23A, Yellow Springs, OH).
insulin and epinephrine determinations were performed by Dr.
Hendler.

Plasma
Rosa

Insulin was measured on pooled samples by radioimmun¬

oassay (62).

Epinephrine was measured on blood samples obtained

at sacrifice by a radioenzymatic assay

(63).

^C-2-D0G radio¬

activity in dissolved muscles was determined in duplicate following
the addition of aquasol

(New England Nuclear,

counting with a Packard spectrometer
3320, Palo Alto,

CA).

Boston, MA)

and

(Packard Instruments, Model

^C-2-D0G uptake is expressed as pmoles of

2-DOG/mg dry wt of tissue-15 min.
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Results

Euglycemic Insulin Clamp
Basal plasma insulin concentration in the post-absorptive
state prior to infusion of insulin averaged 23 ± 2

z^U/ml

(Table 2).

The steady-state plasma insulin concentration during the insulin
clamp study was 55 ± 2 y^U/ml
54 ± 3 y^U/ml at 60 minutes,
/»U/ml at 180 minutes

(Table 2).

Steady-state levels were

55 ± 2 ^U/ml at 120 minutes,

(Figure 1).

and 55 ± 2

The mean increment in plasma

insulin concentration during the 180 minute study period was 31 ± 2
U/ml

(Table 2).

The metabolic clearance rate of insulin was

0.065 ± 0.007 ml/gram body wt -min.

(Table 2).

Basal arterial plasma glucose was 100 ± 1 mg/dl in the postabsorptive state following a 14-16 hour fast,

and was maintained

at 97 ± 2 mg/dl during the 180 minutes of insulin infusion

(Table 2).

Mean plasma glucose varied between 91 ± 2 mg/dl and 108 ± 4 mg/dl
(Figure 1).

The mean coefficient of variation of steady-state

plasma glucose was 11.9 ± 1.3%

(Table 2).

The amount of glucose metabolized

(M)

during the 3 hour study

period of hyperinsulinemia averaged 15.49 ± 0.80
min.

,,*g/g gram body wt*

The rate of glucose metabolism increased rapidly during the

first 40 minutes of insulin infusion and remained constant there¬
after

(Figure 1 and Table 3).
In the control animals,

the fasting plasma insulin averaged

22 ± 1 y^U/rnl and glucose averaged 113 ± 3 mg/dl,
changed during the 180 minute saline infusion

and remained un¬

(Table 4).

Plasma

glucose concentrations were 10-15 mg/dl higher in control animals
than in animals receiving insulin infusions

(Table 4).
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TABLE 3.

Summary of Glucose Metabolism in

Individual Animals During Insulin Clamp

Glucose Metabolism Rate
During Insulin Clamp
_(-/*g/g/min.)_
Time (Min.)
100-140

140-180

13.44

13.78

11.88

13.50

16.72

16.47

13.41

16.31

17.70

17.13
10.55
10.42

16.34
14.36

11.65
7.81

12 .75
9.57
9.22

12.73
11.36
17.00

13.84

15.92

15.69

11.44
15.81

12.88

10.79

-

14.91
17.67

15.04

21.69
14.48

11
12

14.13
16.03
15.28

Subj ect

20-60

60-100

1
2

14.89
18.62

3
4
5

14.53
19.44
11.95

15.98
14.68

6

8.57

7
8
9
10

8.21

20-180

10.91
8.45
14.55
11.62
20.65
14.64

20.74
15.96

20.61

18.76

16.48

15.71

13

10.70

15.16
12.65

12.47

12.30

14

9.69

11.41

8.65

9.13

12.03
9.72

15

15.76

16
17
18

17.43
14.08

16.89
18.59

17.33
20.06

20.73
22.25

17.68
19.58

13.95

14.34

18.46

14.35
19.90

14.98

15.73

20.04

18.53

19
20
21

17.71

25.11

22.18

21.67

19.53
17.07

20.79

20.92

21.69
20.80

20.53

-

-

-

-

22

14.62

14.18

15.31

17.22

15.33

Mean

14.64
±0.98

15.12

15.34

±0.79

±1.01

15.44
±1.00

15.49
±0.80

iSE

28

TABLE 4.

Characteristics of Insulin Infused
and Saline Infused Animals*

SteadyFasting
Plasma

Steady-

State

Fasting

Plasma

Plasma
Insulin

Body Wt.

Glucose

Glucose**

(g)

(mg/dl)

(mg/dl )

{/* U /ml)

State
Plasma
Insulin***
(/‘U/ml)

Saline Controls
(n = 23)

151

±4

113 ± 3+

161

±4

100 ±

109 ± 2^

22 ± 1

21 ± 1

23 ± 2

55 ± 2

Insulin Infused
Animals
(n = 22)

1

97 ± 2

* All values are expressed as means ± SE.
** Represents mean glucose concentrations from 20-180 minutes,
*** Represents mean insulin concentrations from 60-180 minutes.
+ P < 0.001
++

P < 0.005
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Deoxyglucose Transport
Basal 2-deoxyglucose

(2-DOG)

in hyperinsulinemic animals
n = 21) vs.
(p< 0.005).

controls

transport was increased by 42%

(113 ± 7 pmoles/mg day wt

(79 ± 5 pmoles/mg day wt

•

•

15 min,

15 min, n = 24)

Basal transport in hyperinsulinemic animals

plasma insulin concentration = 2.2

(mean

ng/fril) was comparable to insulin-

stimulated transport in soleus muscles from control animals incu¬
bated with 0.75 ng/ml of insulin in vitro.
When soleus muscle from hyperinsulinemic animals was incubated
in vitro with progressively increasing concentrations of insulin
(Figure 2),

insulin-stimulated 2-DOG transport was also increased.

The insulin dose response curve in muscles from hyperinsulinemic
animals was parallel but raised upwards.

The increase in insulin-

stimulated 2-DOG transport was statistically significant at insulin
concentrations of 0.5 ng/ml

(p<0.05)

and 5 ng/ml

(p<0.02).

Al¬

though insulin-stimulated 2-DOG transport was also increased at
insulin concentrations of 0.75,

1.0,

and 10 ng/ml,

did not reach statistical significance.

this difference

When data from the 5 ng/ml

and 10 ng/ml points were pooled to represent a maximally-stimulated
value,

this difference was found to be statistically significant

(p< 0.05).

Dose response curves in muscles from hyperinsulinemic

and control animals were similar when basal 2-DOG transport was
subtracted from insulin-stimulated 2-DOG transport

(Figure 3).

Epinephrine levels prior to sacrifice were somewhat elevated
in hyperinsulinemic animals
pg/ml).

However,

(197 ± 42 pg/ml) vs.

controls

(100 ± 23

this difference was not statistically significant

due to the large amount of scatter in both groups.

Moreover,

was no correlation between epinephrine levels and basal 2-DOG
transport

(r = -0.20).

there

-
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Figure 3.
Insulin-stimulated 2-deoxyglucose (2-DOG) transport in vitro in rat soleus muscles from animals receiving
insulin (A-A) or saline (#-“•) infusions.
Basal transport, in the absence of added in vitro insulin, has been
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Discussion
The present studies have examined the effects of prolonged
(3 hours)

hyperinsulinemia on in vivo glucose metabolism and in

vitro glucose transport in rat soleus muscle.
euglycemic insulin clamp technique

(23)

Modification of the

to the rat has enabled us

to perform these studies under conditions where changes in plasma
glucose concentration are prevented.
Studies by Olefsky et.

al.

(21,

22)

have suggested that chronic

in vivo hyperinsulinemia leads to an increase in basal and maxi¬
mally insulin-stimulated glucose transport in rat adipocytes.
ever,

earlier studies

(19)

How¬

by the same group failed to demonstrate

this effect in a similar model.

In these earlier studies,

an in¬

crease in glucose transport may have been prevented by the failure
to maintain euglycemia in these hyperinsulinemic animals.

Both

changes in plasma glucose and counter-regulatory hormones have been
shown to effect tissue glucose metabolism

(64-70).

Alternatively,

an increase in glucose transport may have already been present in
the control animals, which were both hyperinsulinemic
and relatively hyperglycemic

(152 ± 5 mg/dl).

(29 ± 3/^U/ml)

An increase in

glucose transport in the control group may have masked the differ¬
ence between the two groups.
The present experiments demonstrate an increase in skeletal
muscle glucose transport following 3 hours of physiologic hyper¬
insulinemia in vivo.

This increase in glucose transport was ob¬

served both in the basal state and after stimulation with, insulin
in vitro

(Figure 2).

Similarly,

an increase in maximal insulin-

stimulated glucose transport was also observed,

although data from

the 5 ng/ml and 10 ng/ml points had to be pooled to establish

'

-

-

statistical significance.
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On the other hand,

insulin stimulation

of glucose transport above basal was unchanged

(Figure 3).

Thus,

in vivo hyperinsulinemia causes an activation of basal glucose
transport but appears to have no effect on the ability of the
soleus muscle to respond to additional insulin in vitro.
It could be argued than a carry over of insulin from the in
vivo insulin clamp study into the in vitro transport assay would
account for an increase in basal glucose transport.
ility seems unlikely for the following reasons.

1)

This possib¬
Several steps

are involved which would dilute out insulin from the in vivo study,
including washing the muscles,

a 15 minute preincubation,

hour incubation in insulin free buffer prior to assay.

and a 3

Previous

studies have also shown that washing procedures are effective in
removing in vivo insulin which has stuck to the plasma membrane
before assaying for insulin binding

(71).

2) Physiologically,

insulin carried over from the in vivo study would be additive
with insulin added during the in vitro study and would shift the
dose response curve to the left.

However, maximally stimulated

glucose transport would remain the same and this was not the case.
We also considered the possibility that an increase in basal
and insulin-stimulated glucose transport could be attributed to
the ability of insulin in the plasma during the insulin clamp study
to have access to a compartment which was not accessible during in
vitro exposure to insulin.

This seems unlikely since muscles were

incubated with insulin for 3 hours in vitro and diffusion of insulin
into rat soleus muscle does not appear tc be rate-limiting under
these conditions

(26,

31).

One would expect equilibration of buffer

and interstitial insulin concentrations during the 3 hour incubation.

*
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Persistent activation of the glucose transport system by in
vivo exposure to insulin appears

to be the most likely explan¬

ation for the increase in basal 2-DOG transport observed in vitro.
Basal transport 3 hours after exposure to 55y*U/ml

(2.2 ng/ml)

of

insulin in vivo was 40% greater than in control animals, but was
less than that observed in muscles from control animals exposed
to an equivalent concentration of insulin

(2.2 ng/ml)

in vitro.

This finding may reflect a time-dependent deactivation of insulinstimulated glucose transport.

Basal transport immediately following

exposure to insulin in vivo may in fact have been similar to trans¬
port observed with an equivalent concentration of insulin in vivo.
In this regard,

the time course of deactivation of insulin-

stimulated glucose transport has been studied in the rat adipocyte
following a 60 minute in vitro exposure to 1 ng/ml of insulin
Deactivation of insulin-stimulated 3-0-MG transport had a

(36).

t% of 43

minutes at 37°C and 73 minutes at 24°C in the presence of 1 mM
glucose.

Persistant activation of glucose transport continued

despite a reversal of insulin receptor binding

(36).

Furthermore,

insulin-stimulation of glucose transport persisted unchanged when
deactivation was
and glucose

studied for 2 hours in the absence of both insulin

(36).

Thus,

these results are consistent with the

present experiments which demonstrate a persistent activation of
2-DOG transport in rat soleus muscles 3 hours after in vivo ex¬
posure to insulin.
In addition to an increase in basal 2-DOG transport,

insulin-

stimulated 2-DOG transport was also increased following 3 hours
of in vivo hyperinsulinemia.

An increase in maximal stimulated

transport must represent activation or recruitment of new transport

-
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units from a compartment not accessible to a 3 hour exposure to
insulin in vitro.

If in vivo exposure to insulin caused activa¬

tion of transport units from a fixed compartment,

then further in

vitro insulin-stimulation would not have resulted in the apparent
increase in maximal transport observed in these studies.
The ability of combined in vivo hyperinsulinemia and in vitro
insulin to produce a greater activation of glucose transport than
normoinsulinemia in vivo plus in vitro insulin could have several
explanations.

This effect may be time-dependent and require 6

hours of exposure to increased insulin concentrations,

or alter¬

natively an additional 3 hours may be required following the 3
hour in vivo exposure to insulin for the enhancing effect on glucose
transport to develop.

If either of these explanations were the case,

one would expect that 6 hours of exposure

to either in vivo or

in vitro insulin alone should produce a similar effect.

While

these possibilities cannot be excluded, we think that it is most
likely that some effect of in vivo as opposed to in vitro exposure
to insulin contributes to the observed increase in 2-DOG transport.
Perhaps the acceleration of glucose metabolism achieved during in
vivo hyperinsulinemia is involved in this effect.
We also considered the possibility that other in vivo factors
unrelated to insulin might have an effect which persists through
the 3 hour in vitro incubation prior to assay of glucose transport.
Since the plasma glucose concentration was maintained constant
at the basal level,

it is unlikely that changes in glucose con¬

centration could have contributed to the increase in 2-DOG trans¬
port observed.

Similarly,

although fasting levels of plasma glu¬

cose were slightly lower in hyperinsulinemic animals

(100 vs 113 mg/dl)

36

we would not expect that this small difference in plasma glucose
would account for the increase in 2-DOG transport observed,

es¬

pecially since lower plasma glucose in the normal range has been
correlated with a lower rate of in vivo glucose metabolism.
DeFronzo, personal communication).

(R.

A.

It is also unlikely that

changes in counter-regulatory hormones contributed to the increase
in 2-DOG transport observed since plasma epinephrine levels were
not significantly elevated in hyperinsulinemic animals and there
was no correlation between epinephrine levels and basal transport.
Furthermore,

increases in counter-regulatory hormones,

e.g.,

ep¬

inephrine, would have been expected to have an opposite effect,
namely a decrease in cellular glucose transport, based on previous
in vitro and in vivo studies

(64-70).

Skeletal muscle has been shown to be the principle tissue
responsible for glucose utilization during euglycemic hyperinsulemia (23,

72).

In the present study,

an increase in insulin-

stimulated 2-DOG transport by soleus muscle was documented following
a combined exposure to 3 hours each of in vivo and in vitro insulin.
Nonetheless,

the rate of glucose metabolism during the 140-180 min¬

ute period of the insulin clamp study

(15.44

g/g/min.) was sim¬

ilar to that observed during the 20-60 minute period

(14.64/^g/g/min.).

Several explanations may account for this "apparent discrepancy".
The failure to observe an increase in glucose metabolism
during the 3 hour insulin clamp study may indicate that the in¬
crease in glucose transport is time-dependent and a 6 hour com¬
bined in vivo and in vitro exposure to insulin is required to
produce the increase in 2-DOG transport observed.

Alternatively,
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an increase in glucose metabolism in vivo may have been prevented
by other changes which led to a counter-balancing decrease in
peripheral glucose utilization, but whose effects were dissipated
during the 3 hour incubation period prior to assay of 2-DOG trans¬
port.

In this regard,

a concomitant reversible decrease in re¬

ceptor binding could off-set an increase in glucose transport and
prevent an increase in in vivo glucose utilization.

Although

insulin binding to soleus muscle was not examined in the present
study,

decreased insulin binding to monocytes has been demonstrated

by Soman and DeFronzo
clamp at 100

^

(20)

U/ml in man.

following a 3 hour euglycemic insulin
In addition, regeneration of insulin

receptor binding in adipocytes within 3 hours after chronic in
vivo hyperinsulinemia has been demonstrated by Kobayaski and
Olefsky

(19).

If these results are applicable to soleus muscle,

then a decrease in insulin receptor binding may have counter¬
balanced an increase in the glucose transport system and prevented
an increase in in vivo glucose utilization.

Alternatively,

an

increase in plasma epinephrine during the last period of the insulin
clamp could prevent an increase in glucose metabolism, but have
been dissipated during the 3 hour incubation prior to assay of
2-DOG transport.

This seems unlikely since epinephrine levels

were not significantly elevated and there was no correlation between
epinephrine levels at sacrifice and the rate of glucose metabolism
during the final period of the insulin clamp study.
Recently,

Cushman et.

al.

(41,

42) have proposed that insulin

activation of glucose transport involves the recruitment of glu¬
cose transport units from an intracellular microsomal compartment
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into the plasma membrane.

Based on the present experiments,

extension of this model can be proposed.

an

Prolonged in vivo insulin

stimulation may lead to the recruitment of transport units from
an intracellular pool and the persistent activation of these units
in the plasma membrane, and a subsequent regeneration of the micro¬
somal pool,

so that acute insulin-stimulation will again elicit

a full augmentation of glucose transport and the additive effect
will produce an increase in maximal glucose transport.

The time-

dependence of the increase in maximal glucose transport postulated
in this discussion may in fact represent the synthesis of new
glucose transport units.
In conclusion:

in vivo hyperinsulinemia achieved by the

euglycemic insulin clamp technique results in 1) prolonged activ¬
ation of glucose transport in skeletal muscle manifest as

an in¬

crease in basal transport 3 hours after in vivo exposure to insulin
and 2)

an augmentation of insulin-stimulated glucose transport.
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